Drug exposure The study cohort consisted of new users of GLP-1RAs (dulaglutide, exenatide, liraglutide, lixisenatide or semaglutide), SGLT2 inhibitors (canagliflozin, dapagliflozin or empagliflozin), metformin and other second- or third-line glucose-lowering drugs (thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sulfonylureas, meglitinides, -glucosidase inhibitors, insulin or a combination of glucose-lowering drugs)
Materials and methods Experimental methods Fasting blood samples were collected from fifty non-diabetic subjects and fifty-four diabetic patients at baseline and at follow-up visits after 4 and 8 weeks of anti-diabetic treatment, as described previously in Acharya et al
Aging 12 , 94479460 (2020)
I've had rhinoplasty in the past with another surgeon, and I came in for a consultation with Dr